Protocol Review and Monitoring Committee
The membership of the Protocol Review and Monitoring Committee (PRMC) has been designed to provide broad representation from the various oncology subspecialties, including community oncology, and support areas critical to the success of a clinical research enterprise. This broad representation is necessary to provide high quality and thorough protocol review. All members of the PRMC are full voting members. The Co-Directors of the Cancer Center are ex officio members. The committee meets monthly. See a detailed schedule of committee meeting dates.
|Name/Email||Title/Area of Expertise||Phone||Information|
|Michael Lewis, M.D.
|| Protocol Review and Monitoring Committee Chair;
|Christopher Anker, M.D.||PRMC Vice Chair;
|(802) 847- 3506|
|Steven Ades, M.D.|| Associate Professor
|George Atweh, M.D.||
|Rob Cade, Pharm.D.||Oncology Pharmacist||(802) 847-5577|
|Mark Evans, Ph.D.
|Edmund Folefac, M.D.||
|Alan Howe, Ph.D.||
|Shelly Naud, Ph.D.
|Scott Perrapato, D.O.
|Karen Wilson, C.C.R.P.
||Clinical Trials Supervisor, UVM Cancer Center||(802) 656-4101|
Clinical Research Oversight Committee
The Clinical Research Oversight Committee (CROC) was a senior leadership committee charged with the responsibility for Data and Safety Monitoring. All clinical trials require monitoring, which is performed on a regular basis and is commensurate with the risk and size of the trial. The committee met quarterly. The CROC will be replaced with a Data Safety and Monitoring Committee and will be announced mid-2016.
Last modified October 26 2016 11:26 AM